Astrazeneca agence européenne - activities

Covid: Snubbed, AstraZeneca vaccine moved from 50% to less than 1% of injections performed

AstraZeneca vaccine has been one of the vaccines the most used at the beginning of the vaccination campaign in France. In June 2021, it is snubbed by an overwhelming majority of French people. Worrying side effects, regulations, delivery issues, here is more about the upsetting story of AstraZeneca in France.

AstraZeneca/Janssen: thromboses explained by German searchers

German scientists are said to have discovered where thromboses caused by the AstraZeneca and Janssen vaccines come from, explaining they are caused by the vector used, the adenovirus. Keep reading to find out more.

AstraZeneca vaccine must remain limited to people aged 55+ by the Haute Autorité de Santé says

The Haute Autorité de Santé "maintains the limit of 55 years of age for Vaxzevria", aka AstraZeneca's vaccine, because of the benefit/risk ratio related to rare cases of thrombosis. This notice follows the government's demand as they wish to extend its access to all volunteering French as it is already happening in Germany.

AstraZeneca: the EU to sue the laboratory for not respecting terms of the contract

This Monday April 26, the European Union announced - via the European Commission - they are suing AstraZeneca laboratory for not respecting terms of the contract between the pharmaceutical group and Brussels amid the Covid fight.

AstraZeneca: thromboses considered as "rare side effects" of the vaccine, EMA says

After the Medicines Agency confirmed the existence of a "rare" risk of atypical thrombosis, this Tuesday April 6, the European Medicines Agency declares there is indeed a link between the vaccine and the creation of blood clots. The day after, on Wednesday April 7, the European regulator announced in a press brief they list blood clots as one of vaccine rare adverse effects.

Covid: AstraZeneca vaccine to be renamed Vaxzevria

This Tuesday March 30, the European Medicines Agency announced the AstraZeneca vaccine changed its trade name to become Vaxzevria.

AstraZeneca reviews data and announces vaccine is 76% effective

As this Monday March 22, AstraZeneca laboratory stated their vaccine was 79% effective and show no risk of thromboses (blood clots), this Thursday March 25, the Swedish-British laboratory reviewed data as required by the NIAID (National Institute of Allergy and Infections Diseases), and announced updated data including vaccine was 76% effective.

AstraZeneca vaccine now approved in France for people aged 65-74

After being recommended this past February 10 by WHO for people aged 65+, AstraZeneca vaccine has also been approved in France for people between the age of 65 and 75. This is what Olivier Véran announced on Monday March 1, 2021 on France 2, during an interview.

Covid: AstraZeneca vaccine approved by France's Haute Autorité de Santé for people under 65

Appproved by the European Medicines Agency since this Friday January 29, Covid vaccine by AstraZeneca has been approved, this Tuesday February 2, by the Haute Autorité de Santé only for people under the age of 65. It is to arrive in France from February 8 - according to Secretary of State for European Affairs Clément Beaune.